Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MA09-hRPE in Myopic Macular Degeneration
NCT02122159Phase 2Withdrawn
- Sponsor
- University of California, Los Angeles
- Start
- Mar 2013
- Primary completion
- Jul 2016
- Modality
- Patient-derived iPSCs, Allogeneic iPSCs
01
Overview
A Phase 2 trial of ASP7317 in myopic macular degeneration (MMD), sponsored by University of California, Los Angeles. Planned start Mar 2013; status: withdrawn.
02
Drugs
ASP7317
03
Conditions
myopic macular degeneration (MMD)
Beyond the preview
Go deeper on NCT02122159.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02122159.